Education
About Us
Working with TipRanks
Follow Us
Protagonist Therapeutics (PTGX)
NASDAQ:PTGX
PTGX Stock Chart & Stats
$82.99
-$0.87(-2.26%)
At close: 4:00 PM EST
$82.99
-$0.87(-2.26%)
Day’s Range― - ―
52-Week Range$33.70 - $96.54
Previous CloseN/A
Volume120.35K
Average Volume (3M)722.89K
Market Cap
$5.16B
Enterprise Value$5.09B
Total Cash (Recent Filing)$576.12M
Total Debt (Recent Filing)$10.75M
Price to Earnings (P/E)131.0
Beta0.18
Next Earnings
Mar 18, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.62
Shares Outstanding62,515,667
10 Day Avg. Volume460,827
30 Day Avg. Volume722,895
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.52
Price to Sales (P/S)5.47
P/FCF Ratio13.00
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue24.31
Enterprise Value/Gross Profit24.31
Enterprise Value/Ebitda184.72
Forecast
1Y Price Target
$102.33Price Target Upside23.30% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Results And Regulatory OutlookPhase 3 and extension studies demonstrated durable hematocrit control, reduced reliance on phlebotomy, and a safety profile comparable to placebo, strengthening the case for regulatory approval and physician adoption.
Financing And Capital ReturnsOpting out of the profit-sharing arrangement for the rusfertide program could generate substantial cash proceeds to fund pipeline advancement and support shareholder return initiatives.
Partnership And Royalty ValueThe collaboration framework with U.S. profit sharing and tiered international royalties creates multiple commercialization options and positions future royalty streams as a material, underappreciated valuation driver.
Bears Say
Analyst Conflict Of Interest RiskDisclosed business relationships between analyst firms and covered companies could introduce conflicts of interest that affect report objectivity and influence investor interpretation.
Increased Near-term Financial ObligationsExercising an opt-out could require significant opt-out and milestone payments, raising near-term financial obligations and adding pressure to the company’s cash position.
Strategic And Contractual UncertaintyA limited decision window to pursue a full opt-out creates strategic uncertainty around future royalty terms and commercialization plans, complicating investor assessment of long-term value.
Protagonist Therapeutics News
PTGX FAQ
What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was $33.70 and its highest was $96.54 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is $5.16B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s upcoming earnings report date is Mar 18, 2026 which is in 26 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Nov 06, 2025. The company reported -$0.62 earnings per share for the quarter, beating the consensus estimate of -$0.627 by $0.007.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -0.33.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 62,515,667 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of -$0.62 in its last earnings report, beating expectations of -$0.627. Following the earnings report the stock price went down -0.301%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Currently, no hedge funds are holding shares in PTGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Protagonist Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$102.33 (23.30% Upside)
$102.33 (23.30% Upside)
Blogger Sentiment
Bullish
PTGX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 56.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $17.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 6.7%
Last 30 Days ▼ 6.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
119.84%
12-Months-Change
Fundamentals
Return on Equity
7.80%
Trailing 12-Months
Asset Growth
16.20%
Trailing 12-Months
Company Description
Protagonist Therapeutics
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis, as well as for the treatment of other blood disorders; PN-943, an oral, alpha-4-beta-7 integrin- specific antagonist peptide that is in Phase II clinical trials for treating inflammatory bowel disease (IBD); and PN-235, an orally delivered interleukin-23 receptor specific antagonist for the treatment of IBD and non-IBD indications. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
PTGX Stock 12 Month Forecast
Average Price Target
$102.33
▲(23.30% Upside)
Technical Analysis
ADMA Biologics
―
Zai Lab
―
―
Mirum Pharmaceuticals
―
Ascentage Pharma Group International Unsponsored ADR
―
Ownership Overview
1.33% Insiders
17.51% Mutual Funds
11.64% Other Institutional Investors
45.25% Public Companies and Individual Investors